 |
July-September 2014 Volume 5 | Issue 3
Page Nos. 179-224
Online since Saturday, July 5, 2014
Accessed 56,624 times.
PDF access policy Journal allows immediate open access to content in HTML + PDF
EPub access policy Full text in EPub is free except for the current issue. Access to the latest issue is reserved only for the paid subscribers.
|
| |
|
Show all abstracts Show selected abstracts Add to my list |
|
EDITORIAL |
|
|
 |
Animal experimentation in postgraduate training |
p. 179 |
Ramasamy Raveendran DOI:10.4103/0976-500X.136095 PMID:25210396 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
MINI REVIEW |
 |
|
|
 |
Statin induced diabetes and its clinical implications  |
p. 181 |
Umme Aiman, Ahmad Najmi, Rahat Ali Khan DOI:10.4103/0976-500X.136097 PMID:25210397Statins are one of the most commonly used drugs in the world based on their potential to prevent adverse cardiovascular events. These cholesterol-lowering drugs received a US Food and Drug Administration warning, in February 2012, regarding increased risk of incident diabetes and impaired glycemic control in patients who already have diabetes. The possible association of diabetes with statin therapy has started a wave of discussion in the medical community. A number of meta-analyses conducted in recent years have demonstrated that the association is real although causality has not been proved yet. Individual statins differ with respect to their diabetogenic property; women and elderly persons appear to be at increased risk. Various aspects of statin's adverse effect on glycemic control remain to be explored. As further research in this area continues, physicians might still take some precautions to make risk benefit ratio more favorable for the patients. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (17) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
REVIEW ARTICLE |
 |
|
|
|
Metronomic chemotherapy  |
p. 186 |
Rituparna Maiti DOI:10.4103/0976-500X.136098 PMID:25210398Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called "metronomic chemotherapy" has emerged. Such regimen involves the frequent administration of conventional chemotherapeutic agents at very low doses to target activated endothelial cells in tumors, the advantages of which include minimal adverse effects and a rare chance of developing acquired drug resistance. Previously it was thought that they act by targeting angiogenesis, but recently additional mechanisms have been discovered which has established metronomic chemotherapy as a type of multi-targeted therapy. The knowledge gained from the preclinical studies of metronomic chemotherapy, along with clinical experience, will help to design better therapeutic protocols against cancer. Detailed pharmacogenomic and pharmacoproteomic studies on tumor endothelial cells and large multi-centered clinical trials, integrating bio-marker analyzes, are needed to investigate and validate the best treatment combinations for each tumor type and patient population. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (24) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
RESEARCH PAPERS |
 |
|
|
|
Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis |
p. 193 |
Raffaele Serra, Raffaele Grande, Gianluca Buffone, Edoardo Scarcello, Fabio Tripodi, Pierandrea Rende, Luca Gallelli, Stefano de Franciscis DOI:10.4103/0976-500X.136101 PMID:25210399Objective: To explore the effect of sequential treatment with glucocorticoid and tumor necrosis factor-alpha inhibitors in patients with Takayasu arteritis (TA). Materials and Methods: In five patients with TA, the effects of the sequential treatment with prednisone for 5-7 months and then with adalimumab (ADA) + methotrexate (MTX) or infliximab + MTX, or with ADA only, for 12 months on both clinical and laboratory findings were evaluated. Results: All treatments improved both symptoms and laboratory parameters without the development of side-effects. Conclusions: It was hypothesized that MMP-9 and neutrophil gelatinase-associated lipocalin could be markers of the response to the treatments. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (20) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Antidepressant-like effect of a novel 5-HT 3 receptor antagonist N-(benzo[d] thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide 6k using rodents behavioral battery tests |
p. 197 |
Yeshwant Kurhe, Radhakrishnan Mahesh, Thangaraj Devadoss, Deepali Gupta DOI:10.4103/0976-500X.136104 PMID:25210400Objective: To investigate the antidepressant-like effect of N-(benzo[d] thiazol-2-yl)-3- ethoxyquinoxalin-2-carboxamide 6k, a 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonist using rodents behavioral battery tests. Materials and Methods: 6k screening was performed with behavioral assays for depression-like forced swim test (FST) at several single doses (0.25-4 mg/kg, intraperitoneal injection (i.p.)) to test the potency of 6k, in which 2 and 4 mg/kg doses were found to be most effective and hence, in further behavioral assays including mechanistic model like 5-hydroxytryptophan (5-HTP)-induced head twitches was performed in mice at acute doses of 6k (2 and 4 mg/kg, i.p.). Furthermore, olfactory bulbectomy (OBX), a surgical model-induced behavioral alterations was performed in rats, and the effect of 6k administered orally (2 and 4 mg/kg, p.o.) after subchronic treatment for 14 days starting from day 15 of postsurgery was examined by percent sucrose preference test and modified open field test (OFT). Results: 6k (1, 2, and 4 mg/kg, i.p.) reduced the immobility time and increased the swimming behavior in FST without affecting the baseline locomotor score showing antidepressant-like effect. 5-HTP-induced head twitch response was potentiated by 6k (2 and 4 mg/kg, i.p.), which indicated rise in the serotonergic neurotransmission in the brain. 6k (2 and 4 mg/kg, p.o.) showed anti-anhedonia effect by increasing the sucrose consumption and reversed the behavioral alterations when exposed to modified open field in OBX rats after subchronic treatment for 14 days, thus exhibiting antidepressant-like effect. Conclusion: 6k attenuated the behavioral derangement in rodents-based behavioral battery tests for depression, indicating antidepressant-like potential. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (3) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
RESEARCH LETTERS |
 |
|
|
|
Cannabis use among opioid-dependent individuals on opioid substitution therapy |
p. 203 |
Yatan Pal Singh Balhara, Raka Jain DOI:10.4103/0976-500X.136106 PMID:25210401 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (2) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Sexual dysfunction in alcohol-dependent men on disulfiram or baclofen prophylaxis: A preliminary report |
p. 205 |
Sandeep Grover, Siddharth Sarkar, Naresh Nebhinani, Surendra K Mattoo, Debasish Basu DOI:10.4103/0976-500X.136108 PMID:25210402 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (2) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
CASE REPORTS |
 |
|
|
 |
Hirsutism following the use of bimatoprost eyedrops for glaucoma |
p. 208 |
Subashini Kaliaperumal, Indu Govindaraj, Praveen Kumar Kopparapu, Shashi Ahuja DOI:10.4103/0976-500X.136110 PMID:25210403Prostaglandin F2 alpha (PGF2α) analogues including bimatoprost are often the first line drugs used in the treatment of glaucoma. We present a case of a 62-year-old female patient who was started on bimatoprost in both the eyes for primary open angle glaucoma. The intraocular pressures reached the target level but she developed hair growth over the chin and upper lip after six months of commencing of the treatment. The regional hypertrichosis did not reduce much after stopping the drug. Hirsutism is a potential side effect of prostaglandin analogues which has rarely been reported. Doctors and patients need to be aware of this noticeable and unwanted side effect. The effect seems to occur in patients already having few non-vellus hairs in these areas. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (2) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Netilmicin-induced carpopedal spasm |
p. 211 |
Roja Y Ramani, Benu Panigrahy, Bandana Rath DOI:10.4103/0976-500X.136112 PMID:25210404Aminoglycoside-induced nephrotoxicity is not uncommon. Netilmicin being a member of gentamicin family has the advantage of being relatively free from ototoxicity and nephrotoxicity and is also prescribed for gentamicin resistant cases. In spite of these benefits with netilmicin, occasional development of symptomatic hypomagnesemia, hypocalcemia, and hypokalemia due to renal electrolyte wasting cannot be ruled out. Here we describe two cases of carpopedal spasm due to hypocalcemia following use of netilmicin. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (1) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
 |
Angioedema due to fixed dose combination of telmisartan plus ramipril |
p. 214 |
Vishal R Tandon, Annil Mahajan, Vijay Khajuria, Zahid H Gillani DOI:10.4103/0976-500X.136113 PMID:25210405The risk for angioedema has been suggested lower with angiotensin receptor blockers (ARBs) than with angiotensin-converting enzyme inhibitors (ACEIs) or aliskiren. Many isolated reports do exist, reporting angioedema with ARBs such as olmesartan, valsartan, losartan and telmisartan. To the best of our knowledge this is the first case report of telmisartan plus ramipril fixed dose combination leading to angioedema from India questioning the rationality of ARBs plus ACEIs combination in the treatment of hypertension. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (2) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
Acute delirium in an elderly woman following zoledronate administration |
p. 217 |
Mohammad Nasiruddin, Mohd Fayazuddin, Mohammad Zahid, Syed Iftekhar DOI:10.4103/0976-500X.136115 PMID:25210406Zoledronate is a third-generation bisphosphonate having distinctive profile of high potency as well as prolonged duration of action. Intravenous zoledronate is the recently approved bisphosphonate for the treatment of osteoporosis and has an attractive once-yearly regimen for the treatment of osteoporosis. Here we report, for the first time, a case of acute delirium following zoledronate administration for osteoporosis. An 86-year-old female patient presented to orthopedics out-patient department (OPD) with complaints of pain and unable to bear weight on left thigh with history of fall from bed 2 months back. She was diagnosed as fracture neck of femur with severe osteoporosis and treated conservatively. She was given zoledronate IV 5 mg infusion over 30 min. After 10-12 h of zoledronate infusion, patient became confused, disorientated, and agitated. A septic work-up was negative. Electrolyte disturbances were excluded with normal sodium, potassium, calcium, and magnesium levels. Computed tomography of the brain was unremarkable. A metabolic cause could not be found for the change in her mental state. Patient was referred to medicine department where she was diagnosed as drug-induced acute delirium probably due to zoledronate. Patient was advised injections haloperidol and torsemide. In the following 48 h, her confusion got cleared and mental status was improved. According to the Naranjo's scale, the effect of zoledronate in our patient was scored 6 indicating a probable likelihood of causing delirium. It was a probable cause of acute delirium according to World Health Organization (WHO) causality scale. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (2) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
NEWS AND VIEWS |
 |
|
|
|
News and review |
p. 220 |
G Sivagnanam DOI:10.4103/0976-500X.136116 |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
New(s): Are these terms new(s)!? |
p. 220 |
G Sivagnanam |
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta |
|
|
|
|
|
|
MOLECULES OF THE MILLENNIUM |
 |
|
|
|
Delamanid: A new armor in combating drug-resistant tuberculosis |
p. 222 |
Alphienes Stanley Xavier, Mageshwaran Lakshmanan DOI:10.4103/0976-500X.136121 PMID:25210407Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability. |
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Citations (22) ] [PubMed] [Sword Plugin for Repository]Beta |
|
|
|
|
|